Elizabeth Kornfield Chadwell, MD
Urology · Seaford, DENPI 1245235365
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Procept Biorobotics Corporation at 35.9% of the total. Reporting peaked in 2024 at $1,539 and has fallen 63.6% since, to $561 in 2025.
Across 100 payments — averaging $41.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Astellas Pharma US Inc$620
- C. R. Bard, Inc. & Subsidiaries$475
- Sumitomo Pharma America, Inc.$437
- Bard Access Systems, Inc.$160
- AbbVie$102
- plus $859 from 19 others
What the payments were for
- Consulting fees$63515%
- Travel & lodging$87521%
- Food & beverage$2,16752%
- Education$46111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 12 | $1,486 |
| Astellas Pharma US Inc | 20 | $620 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $475 |
| Sumitomo Pharma America, Inc. | 28 | $437 |
| Bard Access Systems, Inc. | 1 | $160 |
| AbbVie | 4 | $102 |
| Therapeuticsmd, Inc. | 1 | $100 |
| Myriad Women's Health, Inc. | 1 | $89 |
| Ferring Pharmaceuticals Inc. | 4 | $76 |
| Urovant Sciences Inc | 3 | $68 |
| Boston Scientific | 2 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $47 |
| Mylan Specialty L.p. | 2 | $47 |
| Laborie Medical Technologies Corp. | 1 | $45 |
| Pfizer | 3 | $41 |
| AstraZeneca | 1 | $35 |
| Bluewind Medical | 1 | $31 |
| Bayer | 2 | $29 |
| Exeltis, USA Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| KARL Storz Endoscopy-america | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$991
- AquaBeam Robotic System$149
- MYRBETRIQ$125
How this compares
$4,138 in reported general payments places this provider in the 70th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 184 | $151,234 |
| GemtesaVibegron | 126 | $87,091 |
| Estradiol | 113 | $11,531 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 69 | $10,221 |
| Tamsulosin Hcl | 500 | $7,917 |
| Silodosin | 106 | $7,066 |
| Potassium Citrate ErPotassium Citrate | 49 | $6,763 |
| Trospium Chloride ErTrospium Chloride | 31 | $5,904 |
| Mirabegron ErMirabegron | 12 | $5,853 |
| Trospium Chloride | 120 | $4,878 |
| Finasteride | 289 | $4,439 |
| Tolterodine Tartrate ErTolterodine Tartrate | 65 | $3,176 |
| Solifenacin Succinate | 95 | $3,054 |
| Oxybutynin Chloride ErOxybutynin Chloride | 145 | $2,630 |
| Bethanechol Chloride | 46 | $2,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $620 | $151,234184 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $437 | $87,091126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 33 urology providers in Delaware.
Other urology in Seaford
- David CohenSeaford$4K
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Joohyong KimDover$7K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
- Christopher VallorosiDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Bruce BengeWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.